TScan Therapeutics, Inc. (TCRX)
TCRX Stock Price Chart
Explore TScan Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze TCRX price movements and trends.
TCRX Company Profile
Discover essential business fundamentals and corporate details for TScan Therapeutics, Inc. (TCRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Jul 2021
Employees
200.00
Website
https://www.tscan.comCEO
Gavin MacBeath
Description
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
TCRX Financial Timeline
Browse a chronological timeline of TScan Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.35, while revenue estimate is $1.98M.
Earnings released on 12 Aug 2025
EPS came in at -$0.28 matching the estimated -$0.28, while revenue for the quarter reached $3.08M , beating expectations by +65.38%.
Earnings released on 6 May 2025
EPS came in at -$0.26 surpassing the estimated -$0.28 by +7.14%, while revenue for the quarter reached $2.17M , beating expectations by +100.09%.
Earnings released on 5 Mar 2025
EPS came in at -$0.29 falling short of the estimated -$0.27 by -7.41%, while revenue for the quarter reached $665.00K , missing expectations by -56.24%.
Earnings released on 12 Nov 2024
EPS came in at -$0.25 surpassing the estimated -$0.28 by +10.71%, while revenue for the quarter reached $1.05M , missing expectations by -10.54%.
Earnings released on 12 Aug 2024
EPS came in at -$0.28 surpassing the estimated -$0.30 by +6.67%, while revenue for the quarter reached $536.00K , missing expectations by -70.22%.
Earnings released on 13 May 2024
EPS came in at -$0.32 falling short of the estimated -$0.25 by -28.00%, while revenue for the quarter reached $566.00K , missing expectations by -85.76%.
Earnings released on 6 Mar 2024
EPS came in at -$0.21 surpassing the estimated -$0.30 by +30.00%, while revenue for the quarter reached $7.21M , beating expectations by +108.77%.
Earnings released on 9 Nov 2023
EPS came in at -$0.24 surpassing the estimated -$0.43 by +44.19%, while revenue for the quarter reached $3.89M , missing expectations by -12.66%.
Earnings released on 10 Aug 2023
EPS came in at -$0.51 surpassing the estimated -$0.76 by +32.89%, while revenue for the quarter reached $3.15M , missing expectations by -28.03%.
Earnings released on 10 May 2023
EPS came in at -$0.93 falling short of the estimated -$0.73 by -27.40%, while revenue for the quarter reached $6.80M , beating expectations by +39.72%.
Earnings released on 8 Mar 2023
EPS came in at -$0.78 falling short of the estimated -$0.73 by -6.85%, while revenue for the quarter reached $1.00K , missing expectations by -99.98%.
Earnings released on 9 Nov 2022
EPS came in at -$0.67 surpassing the estimated -$0.73 by +8.22%, while revenue for the quarter reached $3.36M , missing expectations by -14.43%.
Earnings released on 10 Aug 2022
EPS came in at -$0.63 surpassing the estimated -$0.76 by +17.11%, while revenue for the quarter reached $4.06M , beating expectations by +35.03%.
Earnings released on 9 May 2022
EPS came in at -$0.67 surpassing the estimated -$0.69 by +2.90%, while revenue for the quarter reached $3.02M , beating expectations by +9.64%.
Earnings released on 9 Mar 2022
EPS came in at -$0.38 surpassing the estimated -$0.73 by +47.95%, while revenue for the quarter reached $2.85M , missing expectations by -17.67%.
Earnings released on 10 Nov 2021
EPS came in at -$0.80 falling short of the estimated -$0.68 by -17.65%, while revenue for the quarter reached $2.41M , missing expectations by -64.02%.
Earnings released on 19 Aug 2021
EPS came in at -$7.69 falling short of the estimated -$2.87 by -167.94%, while revenue for the quarter reached $2.85M , beating expectations by +17.20%.
Earnings released on 15 Jul 2021
EPS came in at -$0.32 , while revenue for the quarter reached $2.03M .
Earnings released on 31 Dec 2020
EPS came in at -$0.33 , while revenue for the quarter reached $795.00K .
Earnings released on 30 Sept 2020
EPS came in at -$0.30 , while revenue for the quarter reached $290.00K .
TCRX Stock Performance
Access detailed TCRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.